-
摘要: 炎症反应是恶性肿瘤发生、发展和转移的重要因素。中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio，NLR)与肾细胞癌患者的预后密切相关，且已被证实可以预测各种实体瘤的结果。本文就NLR在肾细胞癌中的研究进展进行综述，旨在更好地预测肾细胞癌预后及指导治疗决策。
-
关键词:
- 中性粒细胞/淋巴细胞比值 /
- 肾细胞癌 /
- 预后
Abstract: Inflammation is an important factor in the occurrence, development and metastasis of malignant tumors. Neutrophil to lymphocyte ratio(NLR) is closely related to the prognosis of patients with renal cell carcinoma and has been proved to be able to predict the outcome of various solid tumors. This article reviews the research progress of NLR in renal cell carcinoma, in order to better predict the prognosis and guide the treatment decision of renal cell carcinoma.-
Key words:
- neutrophil to lymphocyte ratio /
- renal cell carcinoma /
- prognosis
-
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] 王红心, 樊文龙, 杨晓雨, 等. 亚洲五个国家和地区肾癌负担趋势分析与预测[J]. 华南预防医学, 2023, 49(1): 1-4, 9. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWF202301001.htm
[3] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. doi: 10.3322/caac.21763
[4] National Comprehensive Cancer Network. Kidney cancer(v. 1.2024)[EB/OL]. (2023-06-21)[2023-10-31].
http://www.nccnchina.org.cn/guide/detail/406 [5] Yu WH, Chen GJ, Yan JF, et al. Single-cell sequencing analysis reveals gastric cancer microenvironment cells respond vastly different to oxidative stress[J]. J Transl Med, 2022, 20(1): 250. doi: 10.1186/s12967-022-03411-w
[6] Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer[J]. Sci Rep, 2019, 9(1): 19673. doi: 10.1038/s41598-019-56218-z
[7] Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines[J]. Cold Spring Harb Perspect Biol, 2018, 10(8): a028662. doi: 10.1101/cshperspect.a028662
[8] Li WB, Zhang XH, Chen YK, et al. G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers[J]. Protein Cell, 2016, 7(2): 130-140. doi: 10.1007/s13238-015-0237-2
[9] Liu YY, Zhou NN, Zhou L, et al. IL-2 regulates tumor-reactive CD8+T cell exhaustion by activating the aryl hydrocarbon receptor[J]. Nat Immunol, 2021, 22(3): 358-369. doi: 10.1038/s41590-020-00850-9
[10] Kim TW, Lee JH, Shim KH, et al. Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma[J]. Investig Clin Urol, 2019, 60(1): 14-20. doi: 10.4111/icu.2019.60.1.14
[11] 姚大勇, 史策, 夏舜尧, 等. 术前外周血中性粒细胞/淋巴细胞比值与肾癌临床病理特点及预后关系的研究[J]. 现代生物医学进展, 2016, 16(32): 6379-6383, 6209. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201632047.htm
[12] Allenet C, Klein C, Rouget B, et al. Can pre-operative neutrophil-to-lymphocyte ratio(NLR)help predict non-metastatic renal carcinoma recurrence after nephrectomy?(UroCCR-61 study)[J]. Cancers, 2022, 14(22): 5692. doi: 10.3390/cancers14225692
[13] Hu Q, Mao WP, Wu TG, et al. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients[J]. Front Oncol, 2021, 11: 736640. doi: 10.3389/fonc.2021.736640
[14] Zapała Ł, Slusarczyk A, Garbas K, et al. Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study[J]. Front Biosci, 2022, 14(1): 5.
[15] 杨雷, 李加兵, 陈代, 等. 术前外周血炎症指标对肾癌预后价值的评估[J]. 现代泌尿外科杂志, 2021, 26(7): 587-591. https://www.cnki.com.cn/Article/CJFDTOTAL-MNWK202107010.htm
[16] Adapala RKR, Laxman Prabhu GGL, Sanman KN, et al. Is preoperative neutrophil-to-lymphocyte ratio a red flag which can predict high-risk pathological characteristics in renal cell carcinoma?[J]. Urol Ann, 2021, 13(1): 47-52. doi: 10.4103/UA.UA_34_19
[17] Cheng YL, Kou W, Zhu Y. Preoperative inflammation-associated blood cell markers in patients with non-metastatic clear cell renal cell carcinoma: a retrospective study[J]. Int J Gen Med, 2023, 16: 3067-3080. doi: 10.2147/IJGM.S417948
[18] de Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma[J]. J Urol, 2013, 190(6): 1999-2004. doi: 10.1016/j.juro.2013.06.082
[19] Kim J, Park JS, Heo JE, et al. Neutrophil-to-lymphocyte ratio predicts pathological renal sinus fat invasion in renal cell carcinomas of ≤7 cm with presumed renal sinus fat invasion[J]. Yonsei Med J, 2019, 60(11): 1021-1027. doi: 10.3349/ymj.2019.60.11.1021
[20] Asif A, Chan VW, Osman FH, et al. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for small renal cell carcinomas after image-guided cryoablation or radio-frequency ablation[J]. Cancers, 2023, 15(7): 2187. doi: 10.3390/cancers15072187
[21] 刘涛, 王辉, 王杰, 等. 术前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对肾透明细胞癌的预后评估价值[J]. 临床泌尿外科杂志, 2021, 36(1): 7-11, 17. doi: 10.13201/j.issn.1001-1420.2021.01.002
[22] Parosanu AI, Pirlog CF, Slavu CO, et al. The prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma[J]. Curr Oncol, 2023, 30(2): 2457-2464. doi: 10.3390/curroncol30020187
[23] Teishima J, Ohara S, Sadahide K, et al. Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis[J]. J De L'association Des Urol Du Can, 2017, 11(5): E207-E214.
[24] Keiner C, Meagher M, Patil D, et al. Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: a multicenter analysis[J]. Front Oncol, 2022, 12: 995991. doi: 10.3389/fonc.2022.995991
[25] Nagamoto S, Urakami S, Oka S, et al. Impact of the neutrophil-to-lymphocyte ratio as a surgical prognostic factor in renal cell carcinoma with inferior-vena-cava tumor thrombus[J]. Asian J Surg, 2023, 46(1): 192-200. doi: 10.1016/j.asjsur.2022.03.023
[26] Peyton CC, Abel EJ, Chipollini J, et al. The value of neutrophil to lymphocyte ratio in patients undergoing cytoreductive nephrectomy with thrombectomy[J]. Eur Urol Focus, 2020, 6(1): 104-111. doi: 10.1016/j.euf.2018.08.023
[27] Moran M, Nickens D, Adcock K, et al. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data[J]. Target Oncol, 2019, 14(4): 405-416. doi: 10.1007/s11523-019-00653-5
[28] Patel A, Ravaud A, Motzer RJ, et al. Neutrophil-to-Lymphocyte ratio as a prognostic factor of disease-free survival in postnephrectomy high-risk locoregional renal cell carcinoma: analysis of the S-TRAC trial[J]. Clin Cancer Res, 2020, 26(18): 4863-4868. doi: 10.1158/1078-0432.CCR-20-0704
[29] Templeton AJ, Knox JJ, Lin X, et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy[J]. Eur Urol, 2016, 70(2): 358-364. doi: 10.1016/j.eururo.2016.02.033
[30] Sato MT, Ida A, Kanda Y, et al. Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma[J]. BMC Cancer, 2022, 22(1): 1214. doi: 10.1186/s12885-022-10316-w
[31] Simonaggio A, Elaidi R, Fournier L, et al. Variation in neutrophil to lymphocyte ratio(NLR)as predictor of outcomes in metastatic renal cell carcinoma(mRCC)and non-small cell lung cancer(mNSCLC)patients treated with nivolumab[J]. Cancer Immunol Immunother, 2020, 69(12): 2513-2522. doi: 10.1007/s00262-020-02637-1
[32] Nishiyama N, Hirobe M, Kikushima T, et al. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study[J]. BMC Urol, 2020, 20(1): 110. doi: 10.1186/s12894-020-00679-2
[33] Takada S, Murooka H, Tahatsu K, et al. Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer[J]. Asian Pac J Cancer Prev, 2022, 23(2): 695-701. doi: 10.31557/APJCP.2022.23.2.695
[34] Bilen MA, Rini BI, Voss MH, et al. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial[J]. Clin Cancer Res, 2022, 28(4): 738-747. doi: 10.1158/1078-0432.CCR-21-1688
[35] Iinuma K, Enomoto T, Kawada K, et al. Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab[J]. J Clin Med, 2021, 10(22): 5325. doi: 10.3390/jcm10225325
[36] Rebuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score(Meet-URO 15 study)[J]. Ther Adv Med Oncol, 2021, 13: 17588359211019642. http://pubmed.ncbi.nlm.nih.gov/34046089/
[37] Rebuzzi SE, Cerbone L, Signori A, et al. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second-and third-line cabozantinib[J]. Ther Adv Med Oncol, 2022, 14: 17588359221079580.
-
计量
- 文章访问数: 475
- PDF下载数: 173
- 施引文献: 0
下载: